3-O-Methylfunicone (OMF), a secondary metabolite produced by Penicillium pinophilum, inhibits the in vitro growth of plant pathogenic fungi. This specific property suggested that the compound could be used against other fungal pathogenic activities, including dermatological ones. However, for such applications, toxicological side-effects should be taken into account, in order to prevent other types of risk to mammalian cells. Therefore, investigations were made of the basic toxicity of OMF toward a human tumour cell line. The compound was found to have a cytostatic effect, which represents a counter-indication to its use as a therapeutic agent in dermatology, but suggests that it may have potential as an antitumour agent. This study confirmed the validity of in vitro systems for preliminary assays on new compounds, in order to avoid the use of animals in toxicological studies.
DhedhiB.M., GuptaO., & PatelV.A. (1990). Antagonistic effect of microorganisms to Fusarium oxysporum f.sp. ciceri. Indian Journal of Mycology and Plant Pathology20, 70–71.
2.
AlagesaboopathiC. (1994). Biological control of damping-off disease of cotton seedlings. Current Science66, 865–868.
3.
De StefanoS., NicolettiR., MiloneA., & ZambardinoS.(1999). 3-O-Methylfunicone, a fungitoxic metabolite produced by the fungus Penicillium pinophilum.Phytochemistry52, 1399–1401.
RüeggerA., KuhnM., LichtiH., LoosliH.R., HugueninR., QuiquerezC., & von WartburgA. (1976). Cyclosporin A, ein immunsuppressiv wirksamer peptidmetabolit aus Trichoderma polysporum (Link ex Pers.) Rifai. Helvetica Chimica Acta59, 1075–1092.
6.
ShuteR.E., KawaiM., & RichD.H. (1988). Conformationally constrained biologically active peptides: tentative identification of the antimitogenic bioactive conformer of the naturally occurring cyclic tetrapeptides. Tetrahedron44, 685–695.
7.
ZuccoF. (1992). Use of continuous cell lines for toxicological studies. In In Vitro Alternatives to Animal Pharmacotoxicology (ed. CastellJ.V., & Gomez-LechonM.J.), pp. 43–68. Madrid, Spain: Farmaindustria, Serie Cientifica.
8.
ZuccoF., De AngelisI., & StammatiL. (1998). Cellular models for in vitro toxicity testing. In Animal Cell Culture Techniques (ed. ClynesM.), pp. 395–421. Heidelberg, Germany: Springer–Verlag Lab Manual.
9.
Van Reenen-HoekstraE.S., FrisvadJ.C., SamsonR.A., & StolkA.C. (1990). The Penicillium funiculosum complex: well defined species and problematic taxa. In Modern Concepts in Penicillium and Aspergillus Classification (ed. SamsonR.A., & PittJ.I.), pp. 173–191. New York, NY, USA: Plenum Press.
10.
MooreA.E., SabachewskyL., Wallace ToolanH. (1955). Characteristics of four permanent cell lines of human cancer. Cancer Research15, 598–602.
11.
BorenfreundE., & PuernerJ.A. (1985). Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicology Letters24, 119–124.
12.
ChanceB., & HessB. (1959). Metabolic control mechanisms. I. Electron transfer in the mammalian cell. Journal of Biological Chemistry234, 2404–2412.
13.
GebhardtR. (2000). In vitro screening of plant extracts and phytopharmaceuticals: novel approaches for the elucidation of active compounds and their mechanisms. Planta Medica66, 99–105.
14.
TakahashiM., IwasakiS., KobayashiH., OkudaS., MuraiT., SatoY., Haraguchi-HiraokaT., & NaganoH. (1987). Studies on macrocyclic lactone antibiotics. XI. Antimitotic and anti-tubulin activity of a new antitumor antibiotic rhizoxin and its homologues. Journal of Antibiotics40, 66–72.
15.
ItazakiH., NafashimaK., SugitaK., YoshidaH., KawamuraY., YasudaY., MatsumotoK., IshiiK., UotaniN., NakaiH., TeruiA., YoshimatsuS., IkenishiY., & NakagawaY. (1990). Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. Journal of Antibiotics43, 1524–1532.
16.
LiY., KobayashiH., HashimotoY., & IwasakiS. (1992). Binding selectivity of rhizoxin, phomopsin A, vinblestine and ansatomicin P-3 to fungal tubulins: differential interaction of these antimitotic agents with brain and fungal tubulins. Biochemical and Biophysical Research Communications187, 722–729.
17.
KoisoY., IwasakiS., HanaokaK., KobayashiT., SonodaR., FujitaY., YaegashiH., & SatoZ. (1994). Ustiloxins, antimitotic cyclic peptides from false smut balls on rice panicles caused by Ustalaginoidea virens.Journal of Antibiotics47, 765–773.
18.
MorinoT., MasudaA., YamadaM., NishimotoM., NishikioriT., SaitoS., & ShimadaN. (1994). Stevastelins, novel immunosuppressants produced by Penicillium.Journal of Antibiotics47, 1341–1343.
19.
AndersonH.A., BracewellJ.M., FraserA.R., JonesD., RobertsonG.W., & RussellJ.D. (1988). 5-Hydroxymaltol and mycophenolic acid, secondary metabolites from Penicillium echinulatum.Transactions of the British Mycological Society91, 649–651.
MerliniL., NasiniG., & SelvaA. (1970). The structure of funicone a new metabolite from Penicillium funiculosum.Tetrahedron26, 2739–2749.
22.
KimuraY., YoshinariT., ShimadaA., & HamasakiT. (1995). Isofunicone, a pollen growth inhibitor produced by the fungus Penicillium sp. Phytochemistry, 40, 629–631.
